Vaccines were only injected once in each fish, with a dose of 0.05 ml for ALPHA JECT micro®6 and the ALV405-based vaccine, and 0.1 ml for the commercial SAV vaccine. All vaccinations were done automatically by Lumic vaccination machines (Lumic AS, Norway), according to recommendations from the manufacturers. This implies that fish were vaccinated with the commercial SAV vaccine (December 2nd–14th, 2010) approximately seven weeks prior to injection of ALPHA JECT micro®6, while the ALV405-based vaccine was injected simultaneously with this vaccine. Fish vaccinated with either the commercial SAV vaccine or the ALV405-based vaccine, were held separately until
transfer to the sea cages, where they were mixed to avoid cage effects. Everolimus clinical trial check details The proportion of fish vaccinated with the ALV405-based vaccine was 18.3% and 16.1% in cages 1 and 2, respectively, while the remaining fish were vaccinated with the commercial SAV-vaccine. The groups were identified by removal of the adipose fin for fish vaccinated with the ALV405-based vaccine. Mortalities were recorded daily, and fish health was monitored by an external fish health service.
Official diagnosis of PD was made by the Norwegian Veterinary institute according to their criteria. Mortalities in the study-population were recorded daily until October 5th, 2011. Atlantic salmon (mean weight: 35.5 g) were vaccinated with the monovalent ALV405-based vaccine (0.05 ml dose) or the commercial vaccines ALPHA JECT micro®6 (0.05 ml dose) or ALPHA JECT®6-2 (0.1 ml dose) (n = 35 in each group). Fish were kept at 17 °C water temperature throughout the experiment. Adhesions and melanization of the viscera were recorded 6 and 12 weeks post vaccination (n = 15 per group, per sampling) using a modified Speilberg scale [23]. The efficacy of polyvalent ALV405-based vaccines with different antigenic dose were tested in a intraperitoneal challenge model. Atlantic salmon were tagged, vaccinated and allocated to duplicate tanks according to Table 1. The challenge was
done as described above, except that no cohabitant groups were included, and the challenge isolate ALV407 was Tryptophan synthase used. Efficacy was measured by relative percent survival. The softwares GraphPad Prism 5 and InStat 3 were used for all statistical analyses. Relative percent survival (RPS) was calculated by the following formula: (1 − (% mortality in test group/% mortality in control group)) × 100. The challenge isolate ALV413 caused an accumulated mortality of 87.5% in both parallel tanks in the i.p. challenged fish that had received the PBS placebo vaccine (Fig. 1A). The inactivated ALV405-based vaccine provided a highly efficient protection against mortality with a relative percent survival of 100 and 97 in the two parallel tanks (average RPS = 98.5). It performed significantly better than the commercial SAV vaccine, which gave an RPS of 79 and 51 (Average RPS = 65, p < 0.0001 using Fisher’s exact test).